Brought to you by 
DBV Technologies nets $99mm in Nasdaq IPO
23 Oct 2014
Executive Summary
DBV Technologies SA (Epicutaneous Immunotherapy (EPIT) for severe food allergies), a French company that is already listed on NYSE Euronext Paris, netted $99mm in its initial public offering on Nasdaq. The company sold 2.5mm ordinary shares (including the overallotment) in the form of 4.9mm ADSs at $43.27 per share ($21.64 per ADS) in the US, Canada, and countries beside France. Within France and outside of the US and Canada, DBV completed a concurrent $26mm private placement.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
- Transdermal
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DBV Technologies nets $99mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice